Targeting the tumor-host interface. HRS cells are surrounded by microenvironmental cells, providing a tumor-supportive niche. Novel therapeutic concepts aim at reversion of immunosuppressive features by targeting immune checkpoints on tumor-infiltrating T cells and tumor-associated macrophages as well as by specifically engaging natural killer (NK) cells. CSF1R, colony-stimulating factor 1 receptor.